A Small Molecule Inhibitor of ITK and RLK Impairs Th1 Differentiation and Prevents Colitis Disease Progression

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• Tec kinases IL-2-inducible T cell kinase (ITK) and resting lymphocyte kinase (RLK) are crucial for T cell receptor (TCR) signaling.
• Previous studies on ITK and RLK function in CD4(+) T cells are limited by T cell developmental defects in knockout models.
• A selective small molecule inhibitor, PRN694, allows for precise examination of ITK and RLK inhibition.

Purpose of the Study:

• To investigate the functional consequences of combined ITK and RLK inhibition using the small molecule PRN694.
• To evaluate the efficacy of PRN694 in modulating T helper cell differentiation and cytokine production in vitro.
• To assess the therapeutic potential of PRN694 in a T cell adoptive transfer model of colitis.

Main Methods:

• In vitro Th polarization assays to assess T helper cell differentiation and cytokine production.
• Administration of PRN694 in a T cell adoptive transfer model of colitis.
• Analysis of T cell infiltration, IFN-γ production, P-selectin binding, and chemokine-mediated migration.

Main Results:

• PRN694 potently inhibited Th1 and Th17 differentiation and cytokine production in vitro.
• In vivo administration of PRN694 significantly reduced colitis progression, T cell infiltration, and IFN-γ production.
• PRN694-treated Th1 and Th17 cells exhibited reduced P-selectin binding and impaired migration.

Conclusions:

• Combined inhibition of ITK and RLK effectively suppresses pathogenic T cell responses.
• PRN694 demonstrates therapeutic potential for treating Th1-mediated inflammatory diseases, such as colitis.
• Targeting both ITK and RLK offers a promising strategy for managing inflammatory conditions.